ホームページへ
820К+ 2014年以降患者がサポートを受けています
50
1,500 クリニック
6K+ レビュー
3K+ 3,000名以上の資格を持つ医師

チェコ共和国での癌腫症診断・治療費用について今すぐご確認ください

料金はお問い合わせください
チェコ共和国トルコオーストリア
腹腔内温熱化学療法から $15,000から $22,500から $40,000
データは2026年July月時点でBookimedにより検証され、世界65件のクリニックからの患者リクエストと公式見積もりに基づいています。中央値費用は実際の請求書(2024年-2026年)に基づいており毎月更新されます。実際の価格は異なる場合があります。

Bookimedでのお客様のメリットと保証

直接価格

Bookimedは癌腫症治療価格に追加料金を加算しません。料金はクリニックの公式価格表から来ています。国に到着時にクリニックで治療代を直接お支払いいただきます。

検証済みクリニック・医師のみ

Bookimedはお客様の安全に取り組んでいます。癌腫症治療で高い国際基準を維持し、世界中の国際患者サービスに必要なライセンスを有する医療機関とのみ協力しています。

無料24時間365日サポート

Bookimedは無料専門サポートを提供します。専属医療コーディネーターが治療前、治療中、治療後にサポートし、あらゆる問題を解決します。癌腫症治療の旅路でお一人になることはありません。

なぜ当社を?

Bookimed専属アシスタント

  • すべての段階でサポート
  • 適切なクリニックと医師の選択をサポート
  • 迅速で便利な情報アクセスを確保

チェコ共和国の最高の癌腫症クリニックをご発見ください:1件の認証済み選択肢と料金

クリニックはBookimedのスマートシステムにより、5つの主要基準でのデータサイエンス分析を使用してランク付けされています。

このコンテンツを共有

Bookimed患者のビデオストーリー

Dayana
I combined my vacation in Antalya with a check-up.
治療: 女性検査
クリニック: Memorial Antalya Hospital
Igor
It was great! Transfers, accommodation, treatment—all included.
治療: 歯科インプラント
クリニック: WestDent Clinic
Marina
Bookimed did everything for me. I didn't have to worry about anything.
治療: 女性検査
クリニック: Severance Hospital
更新済み: 05/27/2022
著者
アンナ・レオノヴァ
アンナ・レオノヴァ
コンテンツマーケティングチーム責任者
10年以上の経験を持つ認定医療ライターで、文学修士号を持ち、世界中の医療専門家のインタビューに基づくBookimedの信頼できるコンテンツを開発しています。
Fahad Mawlood
医学編集者・データサイエンティスト
一般開業医。4つの科学賞受賞。西アジアでの勤務経験。アラビア語を話す患者様をサポートする医療チームの元チームリーダー。現在はデータ処理と医療コンテンツの正確性を担当
Fahad Mawlood Linkedin
このページは、さまざまな国で利用可能な各種医療状態、治療、ヘルスケアサービスに関する情報を掲載する場合があります。コンテンツは情報提供のみを目的として提供されており、医療アドバイスやガイダンスとして解釈されるべきではないことをご承知おきください。医療治療を開始または変更する前に、医師または資格のある医療専門家にご相談ください。

チェコ共和国での癌腫症治療に関するFAQ

これらのFAQはBookimedを通じて医療支援を求める実際の患者からのものです。回答は経験豊富な医療コーディネーターと信頼できるクリニック代表者が行います。

What is the most effective treatment for carcinomatosis available in the Czech Republic?

Cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) is the most effective treatment for carcinomatosis in the Czech Republic. This strategy treats peritoneal spread from colorectal, ovarian, and gastric cancers. Specialized centers in Prague and Brno use this protocol to target microscopic cancer cells.

  • Procedure goal: Surgeons remove all visible tumors before circulating heated chemotherapy within the abdomen.
  • Treatment heating: Chemotherapy reaches 41°C to 43°C to enhance drug penetration into cancer cells.
  • Alternative options: Pressurized intraperitoneal aerosol chemotherapy (PIPAC) serves patients who cannot undergo major surgery.
  • Patient selection: Success depends on a manageable peritoneal cancer index and good overall health status.

Bookimed Expert Insight: Czech oncology focuses heavily on multidisciplinary staging before surgery. Centers like the Proton Therapy Center in Prague provide advanced diagnostics including histopathology revisions and radiologist consultations. This rigorous screening ensures that only candidates likely to achieve complete tumor removal undergo the intensive CRS and HIPEC procedure.

Patient Consensus: Patients emphasize finding a surgical team that performs these procedures regularly. They note that the surgeon's ability to remove all visible disease is more important than the specific chemotherapy drugs used.

Who qualifies as a candidate for CRS and HIPEC in Czech hospitals?

Candidates for CRS and HIPEC in Czech hospitals must have peritoneal-confined malignancies that surgeons can completely remove. Patients require an ECOG performance status of 0 or 1. Suitability depends on tumor volume, measured by the Peritoneal Cancer Index, and the absence of extra-abdominal spread.

  • Tumor localization: Disease must stay within the abdomen. Spread to lungs or bones disqualifies patients.
  • Primary cancer types: Includes appendix neoplasms, colorectal cancer, ovarian cancer, or primary peritoneal mesothelioma.
  • Volume cutoffs: Colorectal cases usually require a Peritoneal Cancer Index (PCI) score under 20.
  • Physiological reserve: Patients must have healthy organ function to endure 6 to 12-hour surgeries.

Bookimed Expert Insight: Czech specialized centers utilize diagnostic laparoscopy before finalizing surgery plans. This step reveals small bowel involvement that CT scans often miss. It ensures clinical teams only proceed when a complete cytoreduction is realistically achievable for the patient.

Patient Consensus: Patients emphasize the need for early evaluation before becoming too frail from previous chemotherapy. Choosing a specialized peritoneal team is vital as surgical thresholds can differ between hospitals.

Which hospitals in the Czech Republic specialize in carcinomatosis and perform HIPEC?

Five specialized surgical oncology centers in the Czech Republic perform Cytoreductive Surgery (CRS) with Hyperthermic Intraperitoneal Chemotherapy (HIPEC). These facilities include General University Hospital (VFN), Masaryk Memorial Cancer Institute (MOU), and University Hospital Olomouc. They treat advanced peritoneal metastases from colorectal, ovarian, and gastric cancers.

  • Specialized oncology centers: General University Hospital in Prague has completed over 300 HIPEC procedures.
  • Advanced surgical technology: Masaryk Memorial Cancer Institute in Brno utilizes DaVinci robotic platforms for oncology.
  • Multidisciplinary board review: University Hospital Olomouc uses specialized boards to verify patient eligibility and safety.
  • Peritoneal disease expertise: Motol University Hospital integrates specialized gynecologic oncology units for complex removals.

Bookimed Expert Insight: Czech oncology infrastructure concentrates complex surgeries in university hospitals in Prague and Brno. These centers frequently manage higher patient volumes and multidisciplinary networks. Patients should confirm if a facility treats their specific primary tumor type before traveling. Centers like the Hospital of St. Zdislava focus heavily on robotic-assisted interventions for abdominal cancers.

Patient Consensus: Patients emphasize finding teams that evaluate both cytoreductive surgery and HIPEC together. They recommend preparing imaging and pathology reports early to help university hospital boards triage cases quickly.

What is the life expectancy or survival rate after HIPEC for carcinomatosis?

Modern HIPEC protocols significantly improve survival for carcinomatosis patients. Five-year survival rates range from 70% for appendix cancer to 30-50% for colorectal cases. Outcomes depend on the primary cancer type and achieving complete tumor removal during cytoreductive surgery.

  • Appendix cancer: Reports indicate a 10-year survival rate between 70% and 80%.
  • Ovarian cancer: The 5-year survival rate typically ranges from 24.5% to 56.5%.
  • Colorectal cancer: Median survival reaches 32 to 43 months with complete resection.
  • Gastric cancer: Outcomes are more conservative with median survival under 11 months.

Bookimed Expert Insight: Patient data suggests looking beyond general percentages to the Peritoneal Cancer Index (PCI) score. Centers like the Proton Therapy Center in Prague emphasize specialized diagnostics including histopathology revisions. A PCI score below 13 often correlates with much higher long-term survival rates.

Patient Consensus: Patients note that the surgeon's ability to remove all visible tumors is the most important factor. Many emphasize focusing on recovery timelines and symptom control rather than just looking at survival statistics.

Why does surgical volume or center experience matter for CRS and HIPEC?

Surgical volume determines success in CRS and HIPEC due to a steep institutional learning curve. High-volume centers achieve 99% survival rates and superior tumor clearance. Specialized teams require 140 to 220 cases to reach peak technical proficiency and operational efficiency.

  • Survival rates: Experienced centers report 99% survival compared to 83% at lower-volume facilities.
  • Tumor clearance: Seasoned surgeons more frequently achieve complete removal of all visible abdominal tumors.
  • Patient selection: Experts use the Peritoneal Cancer Index (PCI) to identify ideal surgical candidates.
  • Crisis management: Dedicated oncology teams recognize post-operative complications early to prevent fatal outcomes.

Bookimed Expert Insight: Data shows the Czech Republic houses specialized infrastructure like the Proton Therapy Center in Prague. While regional options exist, carcinomatosis patients should verify annual case counts. Programs performing 30+ procedures yearly typically show more standardized recovery pathways and more consistent success in achieving complete cytoreduction.

Patient Consensus: Patients note that experienced teams often provide more realistic recovery timelines. They emphasize that a center's willingness to decline surgery is actually a sign of high-level expertise.

Can carcinomatosis be treated effectively with standard intravenous chemotherapy alone?

Standard intravenous chemotherapy alone is generally ineffective for curing peritoneal carcinomatosis. The blood-peritoneal barrier limits drug penetration into the abdominal cavity. This creates low therapeutic concentrations. Most patients experience median survival of only 4 to 12 months with systemic drugs alone.

  • Physiological barrier: The peritoneal lining has sparse blood vessels. It blocks circulating intravenous drugs.
  • Survival rates: Outcomes improve when clinicians combine systemic therapy with localized surgical approaches.
  • Tumor response: Peritoneal metastases are less responsive to systemic drugs than liver or lung lesions.
  • Multimodal care: Czech oncology centers often utilize cytoreductive surgery and intraperitoneal heated chemotherapy.

Bookimed Expert Insight: Czech Republic centers like Proton Therapy Center in Prague focus on specialized radiation. However, carcinomatosis requires a surgical oncology landscape. Our data shows patients seeking Czech care often combine systemic chemotherapy with advanced local treatments. Always check if a clinic offers histopathology revision. This simple step can change a carcinomatosis diagnosis and treatment plan entirely.

Patient Consensus: Patients note that intravenous chemotherapy often provides initial symptom relief. However, they emphasize that peritoneal spread usually recurs without a broader multidisciplinary strategy.

無料相談を受ける

最適な連絡方法をお選びください